tetano
Editor, Senior Moderator
Mil Med Res. 2020 Apr 20;7(1):19. doi: 10.1186/s40779-020-00247-7.
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.
Song JC[SUP]1[/SUP], Wang G[SUP]2[/SUP], Zhang W[SUP]3[/SUP], Zhang Y[SUP]4[/SUP], Li WQ[SUP]5[/SUP], Zhou Z[SUP]6[/SUP]; People’s Liberation Army Professional Committee of Critical Care Medicine, Chinese Society on Thrombosis and Haemostasis.
Author information
Abstract
Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.
KEYWORDS:
COVID-19; Coagulation dysfunction; Diagnosis; Severe; Treatment
PMID:32307014DOI:10.1186/s40779-020-00247-7
Free full text
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.
Song JC[SUP]1[/SUP], Wang G[SUP]2[/SUP], Zhang W[SUP]3[/SUP], Zhang Y[SUP]4[/SUP], Li WQ[SUP]5[/SUP], Zhou Z[SUP]6[/SUP]; People’s Liberation Army Professional Committee of Critical Care Medicine, Chinese Society on Thrombosis and Haemostasis.
Author information
Abstract
Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.
KEYWORDS:
COVID-19; Coagulation dysfunction; Diagnosis; Severe; Treatment
PMID:32307014DOI:10.1186/s40779-020-00247-7
Free full text